Recombinant FGF9 protein (ab9745)

Overview

Description

  • NatureRecombinant
  • SourceEscherichia coli
  • Amino Acid Sequence
    • Molecular weight23 kDa

Associated products

Specifications

Our Abpromise guarantee covers the use of ab9745 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications

    Functional Studies

    SDS-PAGE

  • Endotoxin level< 0.100 Eu/µg
  • FormLyophilised
  • Additional notesmFGF-9 is fully biologically active when compared to standards. The ED50, as determined by the dose-dependent stimulation of thymidine uptake by BaF3 expressing FGF receptors, is less than 0.5 ng/ml, corresponding to a specific activity of >2 X 106 units/mg. Murine FGF-9 exerts full activity on both murine and human cells. For most in vitro applications, FGF-9 exerts its biological activity in the concentration range of 0.1 to 20.0 ng/ml.
  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.

    n/a

    This product is an active protein and may elicit a biological response in vivo, handle with caution.

  • ReconstitutionReconstitute using 50ul of sterile H20.

General Info

  • Alternative names
    • FGF 9
    • FGF-9
    • FGF9
    • FGF9_HUMAN
    • Fibroblast growth factor 9
    • GAF
    • Glia Activating Factor
    • Glia-activating factor
    • HBFG 9
    • HBFG9
    • HBGF-9
    • Heparin-binding growth factor 9
    • MGC119914
    • MGC119915
    • SYNS3
    see all
  • FunctionMay have a role in glial cell growth and differentiation during development, gliosis during repair and regeneration of brain tissue after damage, differentiation and survival of neuronal cells, and growth stimulation of glial tumors.
  • Tissue specificityGlial cells.
  • Involvement in diseaseDefects in FGF9 are the cause of multiple synostoses syndrome type 3 (SYNS3) [MIM:612961]. Multiple synostoses syndrome is an autosomal dominant condition characterized by progressive joint fusions of the fingers, wrists, ankles and cervical spine, characteristic facies and progressive conductive deafness.
  • Sequence similaritiesBelongs to the heparin-binding growth factors family.
  • Post-translational
    modifications
    Three molecular species were found (30 kDa, 29 kDa and 25 kDa), cleaved at Leu-4, Val-13 and Ser-34 respectively. The smaller ones might be products of proteolytic digestion. Furthermore, there may be a functional signal sequence in the 30 kDa species which is uncleavable in the secretion step.
    N-glycosylated.
  • Cellular localizationSecreted.
  • Information by UniProt

References for Recombinant FGF9 protein (ab9745)

ab9745 has not yet been referenced specifically in any publications.

Product Wall

Vielen Dank für Ihre Anfrage.

Leider haben wir nicht das passende Blockpeptid für den ab106245 Anti-FGF2 antibody in unserem Katalog, dafür aber das aktive, rekommbinate Protein ab129033:

Click here (or use the following: http://w...

Read More

Thank you for your enquiry. The source of this protein recommends reconstituting it in water. It is supplied as 10ug and can therefore be reconstituted at the concentration required. I hope this information helps, please do not hesitate to cont...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"